Iselin NJ, March 9, 2005 – Pharmos Corporation (Nasdaq: PARS) today reported financial results for the fourth quarter and twelve month period ended December 31, 2004. The net loss for the year increased to $22.0 million, or $0.24 per share in 2004 compared to a net loss of $18.5 million, or $0.27 per share in 2003. Cash and cash equivalents totaled $54.0 million at December 31, […]
Iselin NJ, February 28, 2005 – Pharmos Corporation (Nasdaq: PARS) announced today that it will release financial results for the fourth quarter and full year 2004 on March 9, 2005. Gad Riesenfeld, PhD, President and COO, will host a conference call on the same day at 11:00 AM, EST to discuss recent developments at the Company. In addition to discussing fourth quarter and full year 2004 […]
Iselin NJ, January 25, 2005 – Pharmos Corporation (Nasdaq: PARS) announced today that the Company has received a gross milestone payment of $12.1 million from Bausch & Lomb (NYSE: BOL), its former marketing partner for ophthalmology products. The milestone payment was triggered by Bausch & Lomb’s commercial launch of Zylet™, which was approved for marketing by the FDA on December 15, 2004. Zylet is part of […]